The biotech company Aptadel Therapeutics, a member of CATALONIA.HEALTH, has announced a partnership with the Little Warrior Foundation. The foundation, based in the United States, will provide $500,000 in funding for its therapeutic programme against Ewing's sarcoma, specifically for the pre-clinical phases.

According to the company, the collaboration with the Little Warrior Foundation “reflects its commitment to support innovative solutions for childhood cancer, which continues to be one of the leading causes of child deaths worldwide”. They state that the funding is part of the company's negotiations to attract foreign investment, and, in this sense, they do not rule out the possibility of the US-based foundation becoming a shareholder in future operations.

The spinoff of the Bellvitge Biomedical Research Institute (Idibell) is finalising the completion of a new round of investment of 1.5 million euros, which is expected to be completed this summer. Its main focus is the development of treatment for Ewing's sarcoma, but it is also working on two other platforms, one that also focuses on childhood cancers and the other on diseases affecting adults.

Since its foundation in 2020, the biotech company has raised 1.75 million euros in private investment, in addition to a further 2 million euros in public funding.